These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8828997)

  • 1. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy.
    Rosse RB; Kendrick K; Fay-McCarthy M; Prell GD; Rosenberg P; Tsui LC; Wyatt RJ; Deutsch SI
    Clin Neuropharmacol; 1996 Aug; 19(4):341-8. PubMed ID: 8828997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data.
    Deutsch SI; Rosse RB; Kendrick KA; Fay-McCarthy M; Collins JP; Wyatt RJ
    Clin Neuropharmacol; 1993 Dec; 16(6):518-24. PubMed ID: 9377587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smooth pursuit eye movements in the evaluation of famotidine adjunctive therapy of schizophrenia: a preliminary report.
    Rosenberg PB; Rosse RB; Johri SK; Kendrick K; Fay-McCarthy M; Collins JP; Tsui LC; Wyatt RJ; Deutsch SI
    Clin Neuropharmacol; 1996 Jun; 19(3):276-81. PubMed ID: 8726548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.
    Meskanen K; Ekelund H; Laitinen J; Neuvonen PJ; Haukka J; Panula P; Ekelund J
    J Clin Psychopharmacol; 2013 Aug; 33(4):472-8. PubMed ID: 23764683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Famotidine adjunctive pharmacotherapy of schizophrenia: a case report.
    Rosse RB; Kendrick K; Tsui LC; Fay-McCarthy M; Collins JP; Rosenberg P; Wyatt RJ; Deutsch SI
    Clin Neuropharmacol; 1995 Aug; 18(4):369-74. PubMed ID: 8665550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Famotidine as an adjunct treatment of resistant schizophrenia.
    Oyewumi LK; Vollick D; Merskey H; Plumb C
    J Psychiatry Neurosci; 1994 Mar; 19(2):145-50. PubMed ID: 8204567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
    Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
    J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia.
    Pierre JM; Peloian JH; Wirshing DA; Wirshing WC; Marder SR
    J Clin Psychiatry; 2007 May; 68(5):705-10. PubMed ID: 17503979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group.
    Borison RL; Arvanitis LA; Miller BG
    J Clin Psychopharmacol; 1996 Apr; 16(2):158-69. PubMed ID: 8690831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
    Arvanitis LA; Miller BG
    Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.
    Díaz-Marsá M; Sánchez S; Rico-Villademoros F;
    J Clin Psychiatry; 2009 Apr; 70(4):509-17. PubMed ID: 19358789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of clozapine on symptom clusters in treatment-refractory patients.
    Abraham G; Nair C; Tracy JI; Simpson GM; Josiassen RC
    J Clin Psychopharmacol; 1997 Feb; 17(1):49-53. PubMed ID: 9004057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
    Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
    J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label study of olanzapine in children and adolescents with schizophrenia.
    Quintana H; Wilson MS; Purnell W; Layman AK; Mercante D
    J Psychiatr Pract; 2007 Mar; 13(2):86-96. PubMed ID: 17414684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of galantamine on psychopathology in chronic stable schizophrenia.
    Conley RR; Boggs DL; Kelly DL; McMahon RP; Dickinson D; Feldman S; Ball MP; Buchanan RW
    Clin Neuropharmacol; 2009; 32(2):69-74. PubMed ID: 18978489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
    Chabannes JP; Pelissolo A; Farah S; Gerard D
    Encephale; 1998; 24(4):386-92. PubMed ID: 9809244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.